USA Archives

News and Trends 7 Feb 2023

Endogena Therapeutics retinitis pigmentosa treatment gets FDA fast track designation

The US Food and Drug Administration (FDA) has designated the investigation of Endogena Therapeutics’ EA-2353 for the treatment of retinitis pigmentosa (RP) as a fast track development program. Fast track is a process designed to enable patients to benefit earlier from new drugs for serious conditions. Endogena Therapeutics’ EA-2353 takes a novel, small-molecule approach and […]

February 7, 2023 - 2 minutesmins - By Jim Cornall

In Depth 6 Feb 2023

The biggest private biotech investments in January 2023

The companies Asimov, BioRay Pharmaceuticals and Colossal Biosciences bagged the biggest biotech investments in January 2023. Around the world, synthetic biology players and firms developing treatments for hormonal disorders attracted the biggest funding rounds. 2023 began with a bang in terms of biotech funding, and there are signs of stabilization in biotech stocks after two […]

February 6, 2023 - 4 minutesmins - By Jonathan Smith

News and Trends 3 Feb 2023

Genoscience Pharma receives orphan drug designation for hepatocellular carcinoma drug

Genoscience Pharma has announced that its lead candidate, ezurpimtrostat, a PPT-1 (Palmitoyl Protein Thioesterase-1) inhibitor, has been granted orphan drug designation (ODD) by the US Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC). ODD qualifies ezurpimtrostat for a potential seven years of market exclusivity after approval. The FDA’s ODD program provides […]

February 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 2 Feb 2023

Crown Bioscience acquiring Indivumed’s service business and biobank

Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, has entered into an agreement to acquire the IndivuServ business unit of Indivumed GmbH. A share purchase agreement (SPA) between was executed in December, 2022, and subject to customary closing adjustments, the transaction is expected to close in April 2023. Indivumed […]

February 2, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 2 Feb 2023

Recurv Pharma receives funding for cancer therapy development

Recurv Pharma Inc. is receiving up to $24 million in funding from TVM Capital Life Science through its TVM Life Science Innovation II SCSp fund. Recurv Pharma plans to develop a novel taxane therapy to treat solid tumors to the proof-of-concept stage. The U.S. based biotech firm is the eighth early-stage or project-focused company (PFC) […]

February 2, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 1 Feb 2023

How can patients have access to the latest science?

Innovation in cancer research is happening at an accelerated rate, but the current healthcare system is not equipped to ensure patients can quickly access the latest science. There is a disconnect between treatment innovation and clinical practice. Most cancer patients are seen at community hospitals and treated by generalist oncologists, and data shows that a […]

February 1, 2023 - 6 minutesmins - By Jim Cornall

News and Trends 31 Jan 2023

Stemline Therapeutics’ breast cancer treatment approved

The Menarini Group, an Italian pharmaceutical and diagnostics company, says that the U.S. Food and Drug Administration (FDA) has approved ORSERDU for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Stemline Therapeutics, a wholly-owned subsidiary […]

January 31, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 31 Jan 2023

Stargardt disease treatment gets FDA fast track

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, has announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation (FTD) for MCO-010. MCO-010 is an ambient-light activatable multi-characteristic opsin (MCO) optogenetic monotherapy to restore vision in blind patients, for the treatment of Stargardt disease to […]

January 31, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 31 Jan 2023

Abbisko Therapeutics receives breakthrough therapy designation for CSF-1R inhibitor

Abbisko Therapeutics Co., Ltd. has announced that its CSF-1R inhibitor Pimicotinib has been granted the breakthrough therapy designation from the FDA for the treatment of tenosynovial giant cell tumor (TGCT) patients that are not amenable to surgery. The designation approval is based on results from the phase Ib clinical trial of TGCT cohort for Pimicotinib. […]

January 31, 2023 - 4 minutesmins - By Jim Cornall

CRISPR Therapeutics, CRISPR-Cas9, genome editing, biotech

News and Trends 20 Jan 2023

Aldevron launches type-V CRISPR Nuclease

Aldevron, which develops and manufactures plasmid DNA, RNA and proteins for the biotech industry, has launched Eureca-V Nuclease, the wild-type MAD7 CRISPR Type-V nuclease, licensed from Inscripta, at Research Grade, with GMP to follow.   Aldevron’s launch at Advanced Therapies Week of Eureca-V Nuclease expands the toolkit of available CRISPR nucleases for therapeutic, diagnostic, and agricultural […]

January 20, 2023 - 2 minutesmins - By Jim Cornall

glioblastoma oncolytic virus transgene 2

News and Trends 20 Jan 2023

New drug could replace current standard for treating brain cancer

Glioblastoma (GBM) is a WHO grade IV brain tumor with dismal prognosis. Although post-surgical radiation chemotherapy combined with temozolomide is the standard line of treatment, GBM cells surviving radiotherapy contribute to tumor progression and recurrence even more aggressively. Researchers have now unveiled the mechanism of radioresistance in glioblastoma cells, identifying therapeutic targets to overcome radioresistance. […]

January 20, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 19 Jan 2023

Pathalys Pharma brings in $150M for SHPT trials

Pathalys Pharma, Inc. and Launch Therapeutics (Launch Tx) have announced a collaboration to advance phase 3 clinical trials for upacicalcet (designated PLS240 for clinical trials) for the treatment of secondary hyperparathyroidism (SHPT) in patients on hemodialysis. Launch Therapeutics is backed by funds managed by global investment firm Carlyle and its life sciences franchise Abingworth. Pathalys […]

January 19, 2023 - 3 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

USA

Endogena Therapeutics retinitis pigmentosa treatment gets FDA fast track designation

The biggest private biotech investments in January 2023

Genoscience Pharma receives orphan drug designation for hepatocellular carcinoma drug

Crown Bioscience acquiring Indivumed’s service business and biobank

Recurv Pharma receives funding for cancer therapy development

How can patients have access to the latest science?

Stemline Therapeutics’ breast cancer treatment approved

Stargardt disease treatment gets FDA fast track

Abbisko Therapeutics receives breakthrough therapy designation for CSF-1R inhibitor

Aldevron launches type-V CRISPR Nuclease

New drug could replace current standard for treating brain cancer

Pathalys Pharma brings in $150M for SHPT trials

Subscribe to our newsletter to get the latest biotech news!